Furmonertinib clinical trials
Furmonertinib is named as an intervention in 31 current clinical trials in our China, UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Australia, Taiwan, Singapore, Netherlands, Turkey, Brazil, Mexico and Israel registers. 22 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is ArriVent BioPharma, Inc (3). The most-studied condition is NSCLC.
How Furmonertinib works
All drug targets →- Epidermal growth factor receptor erbB1 inhibitor InhibitorTarget: EGFR epidermal growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Non-small cell lung carcinomaPhase 3
- Leptomeningeal metastasisPhase 2
- Lung adenocarcinomaPhase 2
- Lung cancerPhase 2
- Non-small cell lung adenocarcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297258, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 10477, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Furmonertinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Furmonertinib
- ChEMBL
- CHEMBL4297258
- DrugBank
- DB16087
- PubChem CID
- 118861389
- CAS number
- 1869057-83-9
- FDA UNII
- A49A7A5YN4
- Wikidata
- Q140641519
- Wikipedia
- Firmonertinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Furmonertinib
31 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Furmonertinib
40 conditionsAll 40 conditions
| Condition (as registered) | Trials |
|---|---|
| NSCLC | 5 |
| Non Small Cell Lung Cancer | 4 |
| Non-Small Cell Lung Cancer | 4 |
| Non-small Cell Lung Cancer | 3 |
| EGFR Gene Mutation | 3 |
| Non-Small-Cell Lung Cancer | 2 |
| Metastatic Non-Small Cell Lung Cancer | 2 |
| Advanced Non-Small Cell Lung Cancer | 2 |
| Metastatic Non-Small-Cell Lung Cancer | 1 |
| Advanced Non-Small-Cell Lung Cancer | 1 |
| EGFR P-Loop and Alpha C-Helix Compressing | 1 |
| Adjuvant Treatment | 1 |
| NSCLC (Non-small Cell Lung Carcinoma) | 1 |
| Stage III | 1 |
| EGFR Uncommon Mutations | 1 |
| Non-Small Cell Lung Cancer With EGFR Mutation | 1 |
| Leptomeningeal Metastasis | 1 |
| Intrathecal Chemotherapy | 1 |
| Tyrosine Kinase Inhibitor | 1 |
| Lung Adenocarcinoma | 1 |
| Stage III Lung Cancer | 1 |
| EGFR Positive Non-small Cell Lung Cancer | 1 |
| EGFR Exon 20 Mutations | 1 |
| Non-Small Cell Lung Cancer (NSCLC) | 1 |
| HER2 Exon 20 Mutations | 1 |
| NSCLC Stage IV | 1 |
| Lung Adenocarcinoma Stage III | 1 |
| Lung Adenocarcinoma Stage IV | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| Brain Metastases | 1 |
| Furmonertinib | 1 |
| EGFR Mutation | 1 |
| Advanced Lung Cancer | 1 |
| Non-small Cell Lung Carcinoma | 1 |
| EGFR Exon 20 Insertion Mutation | 1 |
| Lung Cancer (NSCLC) | 1 |
| ALK Gene Mutation | 1 |
| ROS1 Gene Mutation | 1 |
| Non Small Cell Lung Cancer NSCLC | 1 |
| Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
Sponsors
lead sponsor per trial+ 7 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Furmonertinib trials
How many clinical trials are testing Furmonertinib?
31 current trials in our China, UK, USA, France, Spain, Italy, Canada, Japan, South Korea, Australia, Taiwan, Singapore, Netherlands, Turkey, Brazil, Mexico and Israel registers name Furmonertinib (also registered as AST2818) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Furmonertinib trials recruiting patients?
Yes. 22 of the 31 trials are recruiting: 22 with sites in China, 1 with sites in UK, 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Australia, 1 with sites in Taiwan, 1 with sites in Singapore and 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Furmonertinib clinical trials?
ArriVent BioPharma, Inc (3), Allist Pharmaceuticals, Inc (3), Tianjin Medical University Cancer Institute and Hospital (3) and Shanghai Pulmonary Hospital, Shanghai, China (3), among 22 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Furmonertinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Furmonertinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Furmonertinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.